Stockscreener 앱 받기
2.0429
0.35%
-0.0071
Senti Biosciences Inc 주식(SNTI)의 최신 뉴스
What analysts say about Senti Biosciences Inc. stockFree Real-Time Stock Data - Autocar Professional
Is Senti Biosciences Inc. a good long term investmentAccelerated capital growth - jammulinksnews.com
What drives Senti Biosciences Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Senti Biosciences Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times
What makes Senti Biosciences Inc. stock price move sharplyProtected Capital Trading Plan - Newser
Exclusive: Senti Bio CEO Reveals Personal Journey and Strategic Vision for Gene Circuit Platform - Stock Titan
Senti Biosciences Inc. Stock Analysis and ForecastFree Stock Market Return Analysis - jammulinksnews.com
Solid Biosciences Inc. shares rise 3.29% premarket after Senti Bio's presentation at BioScience Forum. - AInvest
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum - The Manila Times
Senti Bio to present logic-gated CAR-NK cell therapy at BioScience Forum - Investing.com
Why Senti Biosciences Inc. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - beatles.ru
Senti Bio Appoints Bryan Baum to Board of Directors, Aims for Growth with New Expertise. - AInvest
Senti Biosciences Appoints Bryan Baum to Board, Enhancing Strategic Direction and Optimizing Value for Stakeholders - AInvest
Bryan Baum Joins Senti Biosciences Board of Directors - AInvest
Sweetgreen, Inc. shares rise 3.77% intraday after Senti Biosciences, Inc. appoints Bryan Baum to its Board of Directors. - AInvest
Senti Biosciences Appoints Bryan Baum to Board - TipRanks
Senti Bio appoints K5 Global co-founder Bryan Baum to board of directors By Investing.com - Investing.com South Africa
Senti Bio appoints K5 Global co-founder Bryan Baum to board of directors - Investing.com
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors - The Manila Times
Is Senti Biosciences Inc. stock overhyped or has real potentialLow Risk ROI Maximization - Newser
How Senti Biosciences Inc. stock performs during market volatilityStrong Buy Recommendations - Newser
SNTI’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Senti Biosciences Stock Faces Decline Amid Market Challenges - timothysykes.com
Senti Biosciences Soars 32.39% on Promising Clinical Trial Results - AInvest
Senti Biosciences (NASDAQ:SNTI) Upgraded by Wall Street Zen to “Sell” Rating - Defense World
Senti Biosciences (NASDAQ:SNTI) Trading Up 2.5% – Here’s What Happened - Defense World
Senti Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Senti Bio Participates in Nasdaq Amplify Spotlight Series - TradingView
Senti Biosciences, Inc.(NasdaqCM: SNTI) added to Russell 3000E Value Index - MarketScreener
SNTI SEC FilingsSenti Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Is Senti Biosciences, Inc. overvalued or undervalued? - MarketsMojo
Senti Bio Reveals Next-Gen Logic-Gated Cell Technology for Precision Cancer Treatment at SEED 2025 - Stock Titan
FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML - Targeted Oncology
Senti Biosciences Inc (SNTI) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Senti Bio Receives US FDA Orphan Drug Designation for Potential Blood Cancer Treatment - MarketScreener
Senti Biosciences, Inc. Reports Progress in Phase 1 Trial of SENTI-202 for Acute Myeloid Leukemia, Receives Orphan Drug Designation - Nasdaq
FDA grants orphan drug designation to Senti Bio’s AML treatment - Investing.com
3.34%
1.44%
자본화:
|
볼륨(24시간):